OptumRx Zepbound Prior Authorization: What Your Doctor Has to Send in 2026

The short answer

OptumRx Zepbound prior authorization comes down to two things: whether your specific plan includes the exact Zepbound device on the prescription, and whether your doctor's records answer that plan's questions. There is no single OptumRx Zepbound checklist that applies to every employer, state program, union, or health plan. The public Optum-administered forms we found show how different the rules can be: one TennCare pathway asks for a starting BMI over 30 — or over 27 with a weight-related condition — while a separate sleep-apnea pathway asks for a qualifying sleep study and a documented CPAP or BiPAP trial. Your own plan can use different criteria.¹²³

Best for you if: your pharmacy card says Optum Rx or OptumRx, and Zepbound was prescribed for chronic weight management or moderate-to-severe obstructive sleep apnea.

Not for you if: the claim is for Mounjaro rather than Zepbound, you are on Medicare and need the separate Medicare lane below, or you are still deciding whether to take Zepbound at all. Type 2 diabetes does not turn a Zepbound prescription into Mounjaro, but Zepbound and Mounjaro have different FDA approvals and plans can place them under different rules.

Now here's the part almost nobody tells you.

There is no single OptumRx Zepbound rule. Optum Rx administers pharmacy benefits for many different clients, and the public documents do not agree on coverage, device preference, renewal requirements, or even which form applies. A current TennCare form marks the Zepbound single-dose pen as preferred. A County of Orange client list excludes the KwikPen and vials while naming the single-dose pen as the alternative. A Michigan external-review order shows that an approval dated into the next year can still die when the employer changes the benefit.²⁴⁵

Which one applies to you was decided by your plan before you ever picked up the prescription.

That's why “what are the OptumRx requirements?” is the wrong first question. The right first question is which rule applies to my plan, and what's actually blocking my claim? This page answers both, using named documents with dates instead of turning one plan's rule into everybody's rule.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Start here: find what's actually blocking you

Answer capsule: A Zepbound claim can stop at eight different points, and each one has a different fix. The message on your screen, pharmacy receipt, member portal, or denial letter tells you which one you're facing. “Prior authorization required” means the plan wants a clinical review. “Not covered” or “excluded” can mean the plan does not include that drug, use, or device — and more clinical paperwork may not fix a true benefit exclusion.

Find your wording. Then read the section it points to.

Nothing above matches your wording? Use this five-question check before you call anyone:

1. What exact plan name is printed on your card?
2. Is Zepbound prescribed for weight management or sleep apnea?
3. Does the prescription say single-dose pen, KwikPen, or vial?
4. Are you starting treatment or renewing it?
5. What exact rejection or denial sentence did you receive?

Write the five answers down. Do not substitute “OptumRx denied it” for the actual message. That one page of notes is enough to keep three different offices from sending you in three different directions.

Why does OptumRx Zepbound coverage have more than one answer?

Answer capsule: Optum Rx is a pharmacy benefit manager. It administers the drug benefit for employers, states, unions, and health plans, but the client controls the benefit design. Optum Rx's own guidance says its standard drug guidelines apply only to plans using its standard drug lists; a member's plan-specific formulary may use different rules.¹

A pharmacy benefit manager, or PBM, runs the pharmacy side of a health plan. That can include the drug list, prior authorization workflow, pharmacy claims, and member cost sharing. But “OptumRx” on the card does not tell you whether your employer bought weight-loss coverage, whether sleep-apnea coverage is included, or whether the KwikPen is treated the same as the single-dose pen.

That matters because your employer, state, union, or health plan picks the coverage design. Optum Rx applies it.

Optum Rx says this itself on its provider page: its standard guidelines are specific to plans that use its standard drug lists, and a plan-specific formulary may not use them. Client formulary documents carry the same warning in a different form: where the drug list and the benefit plan disagree, the benefit plan documents control.¹⁴

That sentence is the most important thing on this page. A state regulator relied on the same basic rule in March 2026 when it upheld an Optum Rx-administered Zepbound denial after an employer changed its benefits. We'll get to that case, because it is the clearest public proof we found of how this plays out outside a clean checklist.⁵

One more thing before we go further

We're going to tell you when a document is silent. That's not us being vague. When a named form does not print an approval length, we say so instead of guessing at one. A confident universal number without a named plan document is not a rule you can safely use.

Your situation changes the answer

The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path, and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized next step before you choose. It takes about two minutes. → /find-my-path/

Is Zepbound even on your OptumRx drug list?

Answer capsule: Check this before anything else. On the County of Orange Optum Rx Premium Formulary exclusions list effective July 1, 2026, Zepbound single-dose pens are named as formulary alternatives while Zepbound KwikPen and Zepbound vials are listed as excluded. That is one client document, not a universal Optum Rx rule — but it proves that a plan can split coverage by device.⁴

Here's what we found in that named client document. We are keeping the client name in the table because the scope is the whole point.

Read row 3 twice. Optum Rx excluded two Zepbound devices and then named a third Zepbound device as the replacement. Same active drug. Same manufacturer. One device is out, one is in.

Two more things from that document that almost nobody has caught:

There's a continuation footnote — and the Zepbound row does not carry it. The list marks certain excluded drugs whose current users may continue coverage. The Zepbound KwikPen and vial row is not marked. On this client list, the continuation note does not protect those two devices.⁴

Mounjaro is on the alternative side in the diabetes section. Mounjaro and Zepbound both contain tirzepatide, but they have different FDA-approved uses and can sit in different rows of a formulary. That's why someone can fill Mounjaro under a diabetes benefit while a Zepbound claim rejects under a weight-management benefit. It can be a benefit-design difference, not a pharmacy mistake.

How to check your own list in about ten minutes

1. Sign in to your Optum Rx member account or app and open the drug-pricing tool or your plan's drug list.
2. Search Zepbound.
3. Write down the exact words you see. Not your summary — the actual words.
4. Open the product detail and find which device it names: single-dose pen, KwikPen, or vial.
5. Look for markers such as PA (prior authorization), QL (quantity limit), ST (step therapy), or an excluded tier.
6. Screenshot the result with the date visible.

If the tool and your pharmacy disagree, ask the pharmacy to run a live test claim and read you the exact rejection message and code. A live claim tests the exact product, pharmacy, quantity, and date. Our guide to GLP-1 pharmacy claim rejection codes explains what comes back.

What “excluded” really means — and the one case that proves it

In March 2026, the Michigan Department of Insurance and Financial Services issued an external-review order naming OptumRx, Inc. as the plan administrator. It is File No. 244942-001-SF, issued March 25, 2026.⁵

The petitioner had been taking Zepbound. In October 2025, their plan announced that starting January 1, 2026, GLP-1 drugs would no longer be covered for weight management or sleep apnea. The notice said existing prior authorizations for those uses would end December 31, 2025.

Then, in November 2025 — after that notice — Optum Rx approved the petitioner's prior authorization through November 10, 2026.

In January, the refill was rejected.

The state Director upheld the denial. The reasoning is worth understanding:

• The plan documents excluded the drug for the petitioner's diagnoses, and the plan documents controlled.
• The petitioner's listed uses — including prediabetes and insulin resistance — were not Zepbound's FDA-approved indications.
• The plan was a governmental self-funded plan, and the Michigan exception law discussed in the order did not apply to that plan. This is a finding about that plan and that Michigan law, not a nationwide rule about every self-funded plan.
• The approval letter dated through November 2026 did not survive the benefit change because the earlier plan notice said existing approvals would end December 31, 2025.

In the public record, the petitioner described feeling “disappointed, discouraged and tired.”

We're including those words because they're an honest description of this experience from a verifiable record, and because a lot of people reading this feel exactly that. It is a real record of an administrative fight — not a claim about how well the medicine works, and not a prediction of what will happen in your case.

The lesson is expensive and specific. The petitioner told the state that earlier clarity could have changed open-enrollment decisions. If you are counting on an approval that crosses into a new plan year, verify it during open enrollment — not in January.

Which Zepbound device do the public Optum documents prefer?

Answer capsule: In the current TennCare forms administered through Optum Rx, the Zepbound single-dose prefilled pen is preferred and the KwikPen is non-preferred on the GLP-1 form. In the County of Orange client exclusion list, the KwikPen and vials are excluded while the single-dose pen is named as the alternative. These are named-plan findings, not a company-wide promise.²³⁴

Zepbound comes in three delivery forms, and a plan may treat them as different products:

The current FDA label includes all three delivery forms. It also says Zepbound's chronic weight-management and sleep-apnea indications are for adults. Safety and effectiveness in pediatric patients have not been established.⁶

Here's the part that trips up real people: the current public TennCare Weight Management Agents form lists the single-dose pen, not the KwikPen, in its Zepbound weight-management row. The separate GLP-1 Agonists form lists the KwikPen as non-preferred and asks for preferred-drug history or a reason the preferred option cannot be used.²³

So if you're using that TennCare pathway and your prescription says KwikPen, you may be trying to walk through a door that isn't in the building.

What to do: call the pharmacy and ask which exact device and NDC are on file. Then ask the prescriber to use the device your plan covers, or document the truthful medical reason the requested device is needed. Two minutes of that beats three weeks of rejections.

If you want the KwikPen on cash pay, see how to get the Zepbound KwikPen online. If you're on Medicare, hold on — the Bridge uses the KwikPen rather than the single-dose pen, and we cover that below.

The rule that quietly kills good requests

Optum Rx publishes this instruction in its electronic prior authorization tutorial: make sure the quantity matches the unit used to dispense the drug. Its own example says pen medications require the number of milliliters, not the number of pens.⁷

Zepbound single-dose pens hold 0.5 mL each. A four-pen supply is 2 mL, not “4.” The KwikPen is different: one pen contains four 0.6 mL doses, for 2.4 mL total.⁶

If someone in the office enters the wrong unit, the request can fail on a number rather than on your medical record.

Ask the office one question: “Was the quantity submitted in the dispensing unit the plan expects — including milliliters where required?” That single question has a better cost-to-benefit ratio than almost anything else on this page.

What do the public TennCare forms actually ask for?

Answer capsule: The two detailed Optum-administered forms we could verify publicly are TennCare forms. They are useful because they show the exact records one real plan asks for, but they are not universal OptumRx rules. The weight form asks adults for a starting BMI over 30 — or over 27 with a weight-related condition — plus current nutrition and lifestyle work. The separate sleep-apnea path asks for a starting BMI over 30, a sleep study showing 15 or more respiratory events per hour, and at least three months of documented CPAP or BiPAP failure unless medically contraindicated.²³

We opened both. Here's what's on them.

Form 1 — TennCare Weight Management Agents

This is the TennCare form for obesity management. On the current copy retrieved August 11, 2026, Wegovy injection and the Zepbound single-dose prefilled pen are listed as preferred, each marked PA and QL.²

What it asks for Zepbound:

• Adults: records supporting a starting BMI above 30, or above 27 with a weight-related condition. The form's examples include high blood pressure, high cholesterol, diabetes, coronary heart disease, MASH/NASH, and obstructive sleep apnea.
• Food and activity: the prescriber attests that the patient is participating in nutrition and lifestyle changes now. The form does not print a six-month diet-program requirement.
• Safety check: personal or immediate-family history of medullary thyroid carcinoma or MEN2.
• No Zepbound-specific step question on this form. The preferred-drug failure questions in that section are labeled for Saxenda and liraglutide, not Zepbound.
• No combination: the form asks whether Zepbound will be used with another FDA-approved obesity drug or another oral or injectable GLP-1 receptor agonist.
• Renewal: the current form asks the prescriber to attest to continued lifestyle work and more than 5% weight loss from baseline.
• One extra month: if the renewal standard is not met, the form says the patient may be approved for one additional month “to allow for titration off medication.” That is the plan form's wording; it is not a general instruction to taper Zepbound on your own.
• Approval length: not printed on the form.

The form contains an under-18 line inside a combined question that also names Wegovy, Saxenda, liraglutide, and Zepbound. Do not read that shared line as proof that Zepbound is approved for children. The current FDA label limits Zepbound's two indications to adults and says pediatric safety and effectiveness have not been established.²⁶

Form 2 — TennCare GLP-1 Agonists

This is the separate TennCare form used for non-obesity indications, including obstructive sleep apnea. Its first routing question sends obesity-management requests to the Weight Management Agents form.³

The sleep-apnea questions ask whether:

• other causes of excessive sleepiness — such as another sleep disorder, a neurological condition, or a medication — have been ruled out;
• the starting BMI was above 30;
• a sleep study showed 15 or more respiratory events per hour;
• CPAP or BiPAP was tried and failed for at least three months, with documented compliance, unless it was medically contraindicated; and
• for a KwikPen request, the record supports use of the non-preferred product instead of the preferred single-dose pen.

For renewal on this form, the printed standard is documentation of a positive clinical response. It does not print a weight-loss percentage for the sleep-apnea renewal question.³

One thing we won't help you do

Do not manufacture a cleaner history. Don't say a drug was tried when it wasn't. Don't fill a prescription just to create a paper trail. Don't add a sleep-apnea diagnosis you don't have, and don't chase a sleep study for the purpose of dodging a weight-loss exclusion.

Two reasons. First, the prescriber attests that the record supports what is on the form. Second, the underlying records can be requested and reviewed.

Everything on this page is about getting the truth in front of the reviewer in the right format. That's a much bigger lever than most people think, and it's the honest one.

What do the public rulebooks prove — and what don't they prove?

Answer capsule: The public documents prove that Optum-administered rules change by client, indication, device, and plan year. They do not prove what your own employer or health plan covers. The useful move is to name the document, its date, and who it applies to every time a number is quoted.

This is the table we built the page around. Nothing here is presented as universal.

Four things that fall out of this table

1. A percentage without a plan name is not enough. The current TennCare form uses “more than 5%.” The UHC commercial weight policy uses “at least 5%.” That one symbol can matter at renewal. Ask for the actual rule in month one.

2. The indication and device can change the entire path. Weight management and sleep apnea can route to different forms. The single-dose pen and KwikPen can sit on different tiers. A correct diagnosis attached to the wrong product or form can still create a dead end.

3. An approval date is only as strong as the benefit behind it. The Michigan order shows a real case where an approval through November 2026 did not survive a January 1 benefit change.

4. Optum Rx doesn't have one Zepbound rule. Your plan does. That is not a contradiction to explain away. It is the answer.

What your doctor has to send

Answer capsule: Optum Rx says missing information can delay a decision or lead to a denial, and its electronic workflow lets the office attach chart notes to the request. The fix is unglamorous: send the records for the pathway your plan actually uses, with dates, on the first try.¹⁷

If you're going through a weight-management pathway

Use your own plan's questions. A packet modeled on the current public TennCare form would include:

• starting weight and BMI, with the date;
• if you already started a GLP-1, the documented baseline from before treatment;
• the qualifying condition if the starting BMI was between 27 and 30;
• a chart note confirming current nutrition and activity work;
• the answer to the medullary thyroid cancer and MEN2 history question;
• the exact Zepbound device, strength, quantity, and days' supply; and
• for renewal, the current weight and calculated change from the documented baseline.

If you're going through a sleep-apnea pathway

A packet modeled on the current public TennCare form would include:

• the sleep-study report, including the AHI or respiratory-event number and the date;
• starting BMI from before Zepbound;
• CPAP or BiPAP dates, length of use, compliance record, and why it failed — or the medical reason it is contraindicated;
• a note addressing other causes of excessive daytime sleepiness;
• the exact device requested and the truthful reason a non-preferred device is needed, if that question applies; and
• any other diagnosis or laboratory record your own plan's questions request.

Five details that cause avoidable delays

1. The form and version. Public plan forms can be replaced at the same web address. Check the plan name and footer before the office submits it.
2. Your identity exactly as printed on the card. Optum Rx's own tutorial says the name and date of birth should match the member's insurance card.
3. The quantity in the requested unit. For pen medicines, Optum's tutorial specifically warns that the quantity may need to be entered in milliliters rather than as a pen count.
4. A working office phone and fax. A request for more information is useless if it lands at an abandoned line or an inbox nobody checks.
5. The chart notes attached to the electronic request. Optum Rx says JPEG, TIFF, and PDF notes can be uploaded inside the ePA workflow instead of sent separately.⁷

### Copy this one-page prescriber checklist Plan name: ______ Exact drug and device: ______ Reason prescribed: weight / sleep apnea / other Starting weight, BMI, and date: ______ Required diagnosis or study attached: yes / no Lifestyle note attached, if required: yes / no Device exception reason attached, if required: yes / no Quantity and days' supply checked: yes / no Case number after submission: ______ Print or copy it. No email gate. Hand it over and let the office work from one clean page.

How OptumRx Zepbound prior authorization gets submitted in 2026

Answer capsule: Electronic prior authorization is Optum Rx's intended route. Optum Rx says it is retiring most pharmacy prior-authorization fax numbers for plans it manages, except in Massachusetts, Rhode Island, South Carolina, and Texas. A verbal request is available at 1-800-711-4555, option 2. Named state programs may still publish their own submission instructions, so the form for your plan wins.¹⁷

If the office says “we'll fax it,” ask which plan-specific fax form it is using. Fax is not automatically wrong, but a generic retired number is.

The move that changes the whole game

We did not find a public, universal commercial Zepbound guideline on Optum Rx's open provider pages. But Optum Rx says members or providers can call 1-800-711-4555 and request its standard drug-specific guideline by fax or mail.¹⁷

Ask for it by name: “Please send me the Optum Rx standard prior authorization guideline for Zepbound, and tell me whether my plan uses that standard guideline or a plan-specific one.”

Now the office is writing to an actual rule instead of guessing. That is the single highest-value phone call on this page.

The four steps, in Optum Rx's own order

1. The office starts a request in an electronic portal and attaches chart notes.
2. Optum Rx reviews it for coverage and, when applicable, sends plan-specific clinical questions.
3. The office answers those questions.
4. Optum Rx sends the result or asks for more information.⁷

Step 2 is why there is no universal checklist. The questions are generated for the member's plan.

One limit on the electronic route

Optum Rx says ePA supports prior authorization and formulary-exception requests, but some cost-reduction requests — such as tiering exceptions, copay waivers, and tier cost-sharing requests — may be excluded. Those go to the PA department by phone at 1-800-711-4555.⁷

Write down these seven things

Submission date. Channel used. Case number. Current status. Any outstanding question. Decision date. Approval start and end dates.

Without a case number, you're calling to ask a stranger about a thing neither of you can find.

How long does OptumRx prior authorization take?

Answer capsule: Optum Rx says electronic requests can be decided two to three times faster than phone or fax, with many determinations made within minutes after a complete submission. That is not a Zepbound promise. The real clock starts when the request is submitted and all requested information is received, not when the prescription was written.⁷

The gap between “a few minutes” and the three weeks you've been waiting can sit in several places: before the office submitted anything, while a plan-specific question was unanswered, after records were requested, or during the plan's review.

The four dates that tell the real story:

1. The date Zepbound was prescribed
2. The date the prior authorization was actually submitted
3. The date more information was requested — and the date it was sent
4. The decision date

Ask for all four. If dates 1 and 2 are weeks apart, the request sat before submission. If date 3 has no response date, that open question is the next move.

The legal outside limit for many job-based plans

For many ERISA-covered employer plans, federal claims rules generally set an outside limit of 15 days for a pre-service decision and 72 hours for an urgent-care claim. The same rule generally gives at least 180 days to appeal an adverse benefit determination. Different coverage types and state rules can use different clocks.⁸

Urgent is not a magic word. Under the federal rule, a claim can qualify as urgent when waiting under the normal clock could seriously jeopardize life, health, or recovery, or cause severe pain that cannot be managed. A treating clinician's judgment matters. Use that lane when it is true, not as a shortcut.

Optum Rx's own guidance makes the simpler point: incomplete information can delay the decision or result in a denial, and completed reviews are made within the timeframe allowed by state or federal law.¹

Your denial letter, decoded

Answer capsule: A denial that says only “does not meet clinical criteria” tells you nothing useful, so the first job is finding out which criterion. There are four different routes back — correction, formulary exception, internal appeal, and external review — and they are not interchangeable. Picking the wrong one costs weeks.

Find your denial reason. Then take the action in that row.

The four lanes, and how to tell them apart

• Correction — something was wrong, incomplete, or mismatched. This is usually the fastest lane.
• Formulary exception — you're asking the plan to cover a drug or device outside its list for a medical reason. That is a different request from ordinary prior authorization. See our GLP-1 formulary exception guide.
• Internal appeal — you're asking the plan to reverse an adverse decision.
• External review — an eligible outside reviewer looks at the decision after the required internal process. The Michigan case above took 21 days from the March 4 filing to the March 25 order, but that is one case, not a guaranteed national clock.⁵

The one call that turns a vague denial into a fixable list

Call the number on your card and say: “My Zepbound request was denied. Please tell me the exact criterion that was not met, the plan document or guideline it came from, and the record that would satisfy it.”

Then ask whether your prescriber can discuss the denial with a reviewer. Optum Rx publishes 1-800-711-4555 for peer-to-peer discussion of prior-authorization denial decisions.⁷

What not to do after a denial

• Don't resubmit the identical packet. Same input, same likely result.
• Don't assume every rejection needs a formal appeal. A device, NDC, quantity, or missing-record problem may need a correction.
• Don't assume a medical-necessity letter automatically defeats a written benefit exclusion. The Michigan case shows why plan language matters.
• Don't let the deadline in your denial notice pass while you wait for someone to call back.

### Match your denial letter to the right appeal Pick the real denial reason before you write anything. The free templates are organized around missing records, clinical criteria, step therapy, formulary exclusions, and other distinct lanes. Open the GLP-1 insurance appeal letter templates →

Approved, but the pharmacy still says no

Answer capsule: An approval and a paid pharmacy claim are two different events. When the pharmacy still rejects Zepbound after approval, compare the approved product against the live claim: device, NDC, strength, quantity, days' supply, pharmacy, and approval dates. This is often a claim mismatch rather than a new medical denial.

Say this at the counter:

“Can you read me the exact rejection message and code, and confirm the product, NDC, quantity, days' supply, and date submitted? My prior authorization number is ___ and the approval dates are ___ to ___.”

Then compare the claim against the approval line by line. A KwikPen can reject when a single-dose pen was approved. A 90-day claim can reject against a 28- or 30-day authorization. A fill can fail before the approval begins or after it ends.

Do not start another appeal until someone has done that comparison.

If you're on Medicare, this is a different lane — and there's a trap

Answer capsule: Traditional Part D does not cover Zepbound when it is prescribed only for weight loss, but it may cover Zepbound for a Part D-covered indication such as moderate-to-severe obstructive sleep apnea, depending on the plan and prior authorization. The separate Medicare GLP-1 Bridge runs outside Part D from July 1, 2026, through December 31, 2027. It covers Zepbound KwikPen only for eligible weight-management patients at a $50 copay per 28-day supply.⁹

Read the next part twice, because it can send you through the wrong door.

CMS says beneficiaries with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with F2–F3 fibrosis are ineligible for the Bridge because those diagnoses can support Part D-covered GLP-1 indications. CMS says that is true even when the person otherwise meets the Bridge's weight criteria. The prescription for a Part D-covered indication should go through the Part D plan instead.⁹

That does not mean every Part D plan automatically covers Zepbound for sleep apnea. It means the Bridge sends that diagnosis back to the Part D lane.

The Bridge's actual clinical criteria

A prescriber must attest that the drug is for weight reduction and maintenance together with ongoing structured nutrition and physical activity, and that the patient was at least 18 when GLP-1 therapy began. The patient must also meet one of these three starting points:⁹

The BMI is measured at GLP-1 therapy initiation, not necessarily on the date of the 2026 Bridge request. CMS gives an example of someone who began with a BMI of 37 and later reached 34; the prescriber attests to the documented starting BMI.⁹

Two doors, and they do not connect automatically

The Bridge starts at the pharmacy, not with a free-floating PA

The order matters:

1. The prescriber sends an eligible prescription to the pharmacy.
2. The pharmacy submits the claim to the Bridge.
3. The pharmacy sends the prior-authorization request to the prescriber, usually within 24–72 hours.
4. The prescriber submits the Bridge form electronically or by fax.
5. CMS says the decision is sent within 72 hours of submission.⁹

Submitting the PA before the pharmacy establishes the claim can return “patient not found.” A Part D denial is not required first. There is no formal Bridge appeal; the office can resubmit if information was wrong or new records are available.⁹

Three more Medicare specifics worth having:

• Pen needles are not covered by the Bridge, and CMS says not to bill them to the patient's Part D plan. The KwikPen needs separately purchased needles.
• The product list can change. CMS says the eligible products and NDCs may be updated during the demonstration.
• The Bridge prescriber help line is 855-273-0102, Monday through Friday, 8 a.m.–7 p.m. Eastern.⁹

A separate Part D workflow issue also matters: Optum Rx says specialty pharmacies can no longer submit a completed Medicare Part D PA through CoverMyMeds on the prescriber's behalf under 42 CFR § 423.566(c). The specialty pharmacy can prepare it and send the request key, but the prescriber must review and submit it.⁷

If you're on Medicare, start here instead: Does Medicare cover Zepbound? and the Medicare GLP-1 Bridge program guide. This page cannot turn a Bridge problem into a standard OptumRx commercial request, and we'd rather send you to the right lane than keep you here.

Renewals, expirations, and what happens when your plan year changes

Answer capsule: Getting approved is the first half. The current TennCare weight-management form asks for more than 5% weight loss from baseline plus continued nutrition and lifestyle work. Its separate sleep-apnea form asks for a positive clinical response without printing a percentage. A UnitedHealthcare commercial weight policy uses at least 5%. And an approval letter with a future expiration date may not survive a benefit change.²³¹⁰⁵

Know your number in month one

If the TennCare weight standard is missed, the form allows one additional month “to allow for titration off medication.” Ask whether that provision applies. Do not change or stop a dose without the prescriber who is treating you.

Your starting weight may be older than you think

A renewal calculation uses the baseline named in the rule. That can be the weight before Zepbound or before GLP-1 therapy, not the weight on the day the renewal form is completed. Make sure the chart contains the baseline number and date the plan asks for.

The math is simple:

Percent lost = (starting weight − current weight) ÷ starting weight × 100

At a 240-pound starting weight, 5% is 12 pounds. “More than 5%” means more than 12 pounds; “at least 5%” includes exactly 12. That is why the wording on the actual form matters.

The plan-year trap

This is the failure mode that hurt the Michigan petitioner, and it's worth stating plainly:

An approval letter does not freeze an employer's future benefit design. In that reviewed case, the open-enrollment notice said existing GLP-1 approvals for weight management and sleep apnea would end December 31, 2025. The Director found that the later approval through November 2026 did not override the 2026 exclusion.⁵

What to do about it, on a real calendar:

1. When open-enrollment materials arrive, search them for “GLP-1,” “weight management,” “obesity,” “sleep apnea,” “Zepbound,” and “formulary.”
2. If coverage is changing, do the cost math before enrollment closes. That is when an FSA election or plan choice may still be available.
3. Ask the benefits team in writing: “Will my existing Zepbound prior authorization remain valid after the benefit change date, or will it end?”
4. Check the device. A plan can keep one Zepbound form and exclude another.
5. Save the approval, plan notice, formulary page, and written answer in one folder.

Five things can stop a working refill: the approval ended, the plan year changed, the benefit design changed, the formulary changed, or the device/quantity on the prescription no longer matches. Check them in that order.

What does Zepbound cost if prior authorization doesn't come through?

Answer capsule: The lowest current manufacturer self-pay prices we verified are $299 per 28 days for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg for the Zepbound KwikPen or four single-dose vials when the Journey Program's refill terms are met. The 7.5 mg through 15 mg price requires a refill within 45 days. Lilly says the regular price after missing that window is $499 for 7.5 mg and $699 for 10 mg, 12.5 mg, or 15 mg. The 2.5 mg dose is an initiation dose, not an approved maintenance dose.¹¹

We're putting the paths in decision order, and we'll tell you where we earn nothing.

The $25 card is not a promise that every covered fill costs $25. Lilly's current terms say the final price depends on the plan's cost sharing and the card's savings caps. Government-funded coverage is not eligible for that commercial savings-card program.¹²

The manufacturer self-pay prices are also not one flat lifelong price. A “month” is 28 days. The high-dose Journey Program price depends on timely refills, and Lilly can change or end the program under its terms.¹¹

The employer door almost nobody checks

Lilly also has an employer-direct Zepbound program for participating self-insured employers. The employer chooses the member's cost sharing, and the program can use a set acquisition price across Zepbound doses outside the normal pharmacy-benefit channel. It is not available just because your employer is self-funded; the employer has to participate.¹³

One email to benefits: “Does our employer offer Zepbound through Lilly Employer Connect or another manufacturer-direct weight-management program outside the standard pharmacy benefit?”

Costs you nothing to ask.

The honest limitation, and why it still helps

Here's the part where we tell you what our recommended option can't do.

Ro cannot make Optum Rx say yes. It cannot submit a prior authorization to your plan unless you become its patient and a Ro-affiliated clinician prescribes the treatment. Its free GLP-1 Insurance Coverage Checker currently checks the Ozempic pen, Wegovy pen, and Zepbound pen. Ro says it cannot check the Zepbound KwikPen through that free tool. The checker asks for insurance-card information, contacts the insurer, and sends a report; it does not write a prescription or submit a treatment request.¹⁴

If your prescription is for the KwikPen or a vial, or your employer excluded weight-management drugs outright, the free checker may not answer the question you actually have. If that's you, don't pay anyone yet. Go to our KwikPen page, formulary exception guide, or cash-pay Zepbound breakdown instead. Those are free and they're the right tools for your problem.

But that limitation is the same reason the checker is useful. It gives you a written answer about the products it checks before a treatment membership is required. If you need a new prescriber and insurance support after that, Ro says its paid program includes an insurance concierge that handles coverage paperwork.

That's the trade. If your current prescriber's office has a capable prior-authorization team, ask them first. If it does not, paying for a care team that will own the paperwork can be worth the fee.

Provider-stated vs. what we verified on August 11, 2026

Ro's published membership price is $39 for the first month, then $74 per month on an annual prepaid plan, $89 per month on a six-month prepaid plan, $99 per month on a three-month prepaid plan, or $149 month to month. Medication is separate.¹⁵

### See what your plan will pay before you start treatment Ro's checker is free and produces a written coverage report for the products it supports. It does not prescribe, enroll you in treatment, or submit a treatment request by itself. Check Zepbound coverage with Ro → (affiliate link; opens in a new tab) Prefer another telehealth option for FDA-approved Zepbound? Sesame says clinicians in its Success by Sesame program can help with prior-authorization paperwork. See our Sesame Care review.¹⁶

One thing we won't do: we're not listing a compounded provider as a substitute for insured Zepbound on this page. Compounded tirzepatide is not FDA-approved Zepbound. FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed, and compounded products should not be represented as the approved brand.¹⁷

What if your plan truly excludes Zepbound?

Answer capsule: Before you spend weeks on paperwork, confirm how wide the exclusion is. Ask whether it covers every Zepbound device, both FDA-approved uses, and every exception route. A plan exclusion, a formulary exclusion, and a device rejection are not the same problem.

Four questions, in this order. Send them by email so you have the answers in writing.

1. Does the exclusion apply to every Zepbound device, or only some? The County of Orange list excluded the KwikPen and vials while naming single-dose pens as alternatives.
2. Does it apply to both FDA-approved uses, or only weight management? Zepbound is FDA-approved for chronic weight management in qualifying adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.⁶
3. Does the plan allow a formulary or coverage exception, and what is the process and deadline? Get the rule, not an opinion.
4. What kind of plan is this, and which law governs it? The Michigan order shows that one governmental self-funded plan was outside a specific Michigan exception law. It does not prove that every self-funded plan is outside every state protection.⁵

A script you can copy:

“My pharmacy benefit is administered by Optum Rx. My plan documents show [exact wording] for [exact Zepbound device]. Is this an employer-selected benefit exclusion, a formulary exclusion, or a device-specific rule? Does it apply to both FDA-approved indications? Does the plan allow an exception, and what is the process and deadline?”

If the answer is a firm no across the board, stop paying for duplicate paperwork and look at real cost math: cheapest Zepbound without insurance, the Zepbound savings card, or a covered alternative on your OptumRx drug list.

Safety, briefly

Answer capsule: This is an insurance guide, not a prescribing guide. Zepbound is FDA-approved for chronic weight management in qualifying adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Its label carries a boxed warning about thyroid C-cell tumors observed in rats and says not to use it in people with a personal or family history of medullary thyroid carcinoma or MEN2.⁶

Four things worth saying out loud:

• An insurance approval does not mean the medicine is right for you.
• An insurance denial does not mean it is wrong for you.
• Do not change or stop your dose while you fight a claim without talking to your prescriber.
• If you're having urgent symptoms, get care. Don't wait on a coverage decision.

Review the current prescribing information with your clinician. This page is information, not medical advice.

What we actually verified

Answer capsule: Every rule on this page is tied to a named document and scope. We list dates because forms and program pages change. Here is what we checked on August 11, 2026, and what only your own plan can answer.

What we opened and read

What we could not verify from public documents

• Your plan's coverage. Only your current plan documents, member portal, and live claim can answer that.
• A public commercial Zepbound guideline that applies to every OptumRx client. Optum says standard guidelines may not apply to plan-specific formularies.
• A Zepbound-specific OptumRx approval rate, denial rate, or average turnaround time.
• Whether the public TennCare forms match the questions generated for any non-TennCare plan.
• Whether a future plan-year approval will survive a benefit change. That must be confirmed against the new plan documents.

We excluded claims we could not tie to a current primary source, a named plan, or a live provider page. The thing that makes a page trustworthy isn't confidence. It's knowing where the edges are.

Frequently asked questions

Does OptumRx require prior authorization for Zepbound?

The current public TennCare forms administered through Optum Rx mark the covered Zepbound products with PA and quantity-limit markers. That does not prove every OptumRx plan requires PA or covers Zepbound. Check the exact device in your member portal or drug list, then have the pharmacy run a live claim.²³

What BMI does OptumRx require for Zepbound?

There is no universal public OptumRx BMI rule. On the current TennCare weight-management form, the adult starting point is BMI over 30, or over 27 with a listed weight-related condition. On its separate sleep-apnea pathway, the starting BMI is over 30. Your plan can use different criteria.²³

Does OptumRx require step therapy for Zepbound?

Not on the Zepbound section of the public TennCare weight form we reviewed. Its preferred-drug failure questions in that section are labeled for Saxenda and liraglutide. But the separate TennCare GLP-1 form marks the Zepbound KwikPen non-preferred and asks questions about use of preferred products. Device choice and plan rules can therefore change the answer.²³

What is the OptumRx prior authorization phone number?

1-800-711-4555. Optum Rx says to press option 2 for a verbal prior-authorization request. Its electronic-PA page lists hours of Monday through Friday, 5 a.m.–10 p.m. Pacific, and Saturday, 6 a.m.–3 p.m. Pacific; Sunday is closed. The same number is listed for requesting standard drug-specific guidelines and discussing a denial.⁷

Can my doctor still fax the Zepbound prior authorization?

Sometimes. Optum Rx says it is retiring most pharmacy PA fax numbers for plans it manages except in Massachusetts, Rhode Island, South Carolina, and Texas, and it strongly encourages electronic submission. But named state and program forms can still publish their own fax instructions. Use the submission method on the current form for your actual plan.¹

How long does OptumRx prior authorization take for Zepbound?

Optum Rx says electronic PA decisions can happen two to three times faster than phone or fax and that many are made within minutes after submission. That is general ePA information, not a Zepbound guarantee. The clock depends on when a complete request was submitted, whether the office answered follow-up questions, and the legal timeframe for your coverage.⁷¹

Does OptumRx cover the Zepbound KwikPen?

Some plans may, but the public documents we reviewed do not support a universal yes. The current TennCare GLP-1 form marks the KwikPen non-preferred. The County of Orange client exclusion list effective July 1, 2026, excludes it and names the single-dose pen as an alternative. The Medicare GLP-1 Bridge does the opposite and includes the KwikPen rather than the single-dose pen.³⁴⁹

Does OptumRx cover Zepbound vials?

It depends on the plan. The County of Orange client list we reviewed excludes Zepbound vials. LillyDirect separately offers the single-dose vial as a self-pay-only product. Check your own formulary before treating one client's exclusion as your rule.⁴¹¹

Does OptumRx cover Zepbound for sleep apnea?

Some Optum-administered plans do. Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, and the current TennCare GLP-1 form has a dedicated pathway asking for a starting BMI over 30, a sleep study with at least 15 respiratory events per hour, and a three-month documented CPAP or BiPAP trial unless contraindicated. FDA approval does not create coverage; the plan still decides.⁶³

How much weight do I have to lose to keep Zepbound approved?

The current TennCare weight form says more than 5% of baseline weight. The UHC commercial weight policy we reviewed says at least 5%. The TennCare sleep-apnea form uses “positive clinical response” without printing a percentage in that renewal question. Ask which named rule applies before month six.²³¹⁰

Can I get the actual OptumRx criteria for Zepbound?

You can ask for them. Optum Rx says to call 1-800-711-4555 and request its standard drug-specific guideline by fax or mail. Also ask whether your plan uses that standard guideline or a plan-specific one, because Optum's own page warns that standard guidelines may not apply to a plan-specific formulary.¹

Does my old Zepbound approval survive a plan change?

Not always. In the March 2026 Michigan order, a member held an approval through November 10, 2026, but the plan's earlier benefit notice ended existing weight-management and sleep-apnea approvals on December 31, 2025. The denial was upheld under that plan and governing rules. Confirm cross-year approvals in writing during open enrollment.⁵

My OptumRx plan excluded weight-loss drugs. Is there anything left to try?

Yes, in this order: confirm whether the exclusion covers every Zepbound device and both approved uses; ask for the exception process and deadline in writing; ask whether an employer-direct manufacturer program exists; then compare cash prices. If it is a true plan-wide exclusion, more copies of the same PA packet will not turn it into covered medicine.

Does Medicare with OptumRx cover Zepbound?

Regular Part D may cover Zepbound for a Part D-covered indication such as moderate-to-severe obstructive sleep apnea if the plan lists it and its criteria are met. The separate Medicare GLP-1 Bridge covers Zepbound KwikPen for eligible weight-management patients at $50 per 28-day supply through December 31, 2027. CMS says people with type 2 diabetes, moderate-to-severe sleep apnea, or qualifying MASH are ineligible for the Bridge and should use the Part D lane.⁹

What do I do first if my Zepbound prior authorization was denied?

Get the exact denial wording and the specific criterion that failed. Then choose the right lane: correct a missing or wrong fact, request a formulary exception when the product is off-list, file an internal appeal when the decision should be reversed, or pursue external review when eligible after the required internal process. Resubmitting the same packet without fixing anything is the most common wasted step.

Still not sure which GLP-1 program fits your situation?

Coverage is only one piece of this. Your state, plan drug list, treatment preference, budget, and need for insurance help can point to different paths.

Still not sure which GLP-1 program is right for you? Take our free matching quiz. It takes about two minutes.

Get my personalized action plan →

How we made this guide

We opened Optum Rx's public prior-authorization process pages, two current TennCare forms, a July 2026 County of Orange client exclusion list, the FDA label, a March 2026 Michigan external-review order, a current UnitedHealthcare commercial policy, CMS's Medicare GLP-1 Bridge guidance, and the current manufacturer and provider pages on August 11, 2026. We recorded each document's name, date, and scope. Where a document is silent, we say it is silent. Where a public state form does not apply to everyone, we name the state instead of calling it “the OptumRx rule.”

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. We are not a medical provider. This page is information, not medical advice.

Sources

1. Optum Rx, “Prior Authorization Guidelines and Procedures,” accessed August 11, 2026: https://business.optum.com/en/support/professionalrx-resources/pa-guidelines-procedures.html
2. Optum Rx/TennCare, “Weight Management Agents Prior Authorization Form,” current file retrieved August 11, 2026: https://contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/Tenncare/Obesity-Management-Agents-PA-Form.pdf
3. Optum Rx/TennCare, “GLP-1 Agonists Prior Authorization Form,” version 07/2026 v2, retrieved August 11, 2026: https://contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/Tenncare/GLP-1-Agonists-PA-Form.pdf
4. Optum Rx/County of Orange, “Premium Formulary Reference Guide: Exclusions and Formulary Alternatives,” effective July 1, 2026: https://contenthub-aem.optumrx.com/content/dam/contenthub/onboarding/assets/countyoforange/exclusions-psp-july-2026.pdf
5. Michigan Department of Insurance and Financial Services, External Review Order, File No. 244942-001-SF, issued March 25, 2026: https://www.michigan.gov/difs/-/media/Project/Websites/difs/PRIRA/2026/March/OptumRx_244942.pdf
6. U.S. Food and Drug Administration, Zepbound prescribing information, revised January 2026: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
7. Optum Rx, “Electronic prior authorization,” accessed August 11, 2026: https://business.optum.com/en/pharmacy-services/electronic-prior-authorization.html
8. Electronic Code of Federal Regulations, 29 CFR § 2560.503-1, current through August 11, 2026: https://www.ecfr.gov/current/title-29/subtitle-B/chapter-XXV/subchapter-G/part-2560/section-2560.503-1
9. Centers for Medicare & Medicaid Services, “Medicare GLP-1 Bridge: Information for Providers,” page updated August 6, 2026 and accessed August 11, 2026: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
10. UnitedHealthcare, “Weight Loss – Prior Authorization/Notification,” policy effective July 1, 2026: https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf
11. Eli Lilly and Company, “Zepbound at LillyDirect,” accessed August 11, 2026: https://www.lilly.com/lillydirect/zepbound
12. Eli Lilly and Company, “Zepbound Savings & Insurance Options,” accessed August 11, 2026: https://zepbound.lilly.com/savings
13. Eli Lilly and Company, “Zepbound for Employers,” accessed August 11, 2026: https://zepbound.lilly.com/employer
14. Ro, “GLP-1 Insurance Coverage Checker,” accessed August 11, 2026: https://ro.co/weight-loss/glp1-insurance-checker/
15. Ro, “Weight Loss Program Pricing,” accessed August 11, 2026: https://ro.co/weight-loss/pricing/
16. Sesame, “Get a Zepbound Prescription Online,” accessed August 11, 2026: https://sesamecare.com/medication/zepbound
17. U.S. Food and Drug Administration, “Compounding and the FDA: Questions and Answers,” and “FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s,” accessed August 11, 2026: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers and https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s